Abstracts tagged "Psoriatic arthritis"

Abstract Number: 2309 • ACR Convergence 2025
Lifestyle behaviours and disease activity in patients with psoriatic arthritis: the Dutch south west psoriatic arthritis study
Batoul Hojeij¹, Ilja Tchetverikov², Marijn Vis¹, Marc R Kok³, Yvonne Goekoop-Ruiterman⁴, Jessica Bijsterbosch⁵, Paul Baudoin⁶, Reinhard Bos⁷, Jos H van der Kaap⁸, Petra Kok⁹, Lindy-Anne Korswagen¹⁰ and Jolanda J Luime¹, ¹Erasmus MC, Rotterdam, Netherlands, ²Albert Schweitzer Hospital, Dordrecht, Netherlands, ³Maasstad Hospital, Rotterdam, Netherlands, ⁴Haga Hospital, the Hague, Netherlands, ⁵Amphia Hospital, Breda, Netherlands, ⁶Reumazorg Zuid West Nederland, Roosendaal, Netherlands, ⁷Medisch Centrum Leeuwarden, Leeuwarden, Netherlands, ⁸Admiraal De Ruyter Hospital, Goes, Netherlands, ⁹Reinier de Graaf Hospital, Delft, Netherlands, ¹⁰Franciscus Gasthuis and Vlietland, Rotterdam, Netherlands
Background/Purpose: Comprehensive assessment of multiple lifestyle behaviours and disease activity outcomes in psoriatic arthritis (PsA) is scarce. We aim to investigate lifestyle behaviours in patients…
Abstract Number: 1715 • ACR Convergence 2025
Spondyloarthritis and Psoriatic Arthritis Patients Under Immunosuppressive Conventional and Biologic DMARDs: Favorable Disease Safety and Attenuated Immunogenicity Following Recombinant Herpes Zoster Vaccination
Carla Saad¹, Eduardo Borba², Fernanda Chaer³, Ana C Medeiros-Ribeiro¹, Sandra G Pasoto¹, Nadia Emi Aikawa⁴, Luisa Correia⁵, Percival Sampaio-Barros⁶, Julio Moraes⁷, Murillo Dorio¹, Claudia Goldenstein-Schainberg¹, Clovis Artur Silva⁸ and Eloisa Bonfa², ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ²Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Santos, Brazil, ⁴Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, São Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, ⁶Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Brazil, ⁷Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Jundiai, Brazil, ⁸University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: Psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) patients are at increased risk for herpes zoster(HZ) due to impaired cell-mediated immunity associated with the underlying…
Abstract Number: 1453 • ACR Convergence 2025
Real-World Comparative Effectiveness of Upadacitinib in Psoriatic Arthritis: Evaluation of Switching to Upadacitinib Versus Tumor Necrosis Factor Inhibitors or Interleukin-17 Inhibitors After First-Line Tumor Necrosis Factor Inhibitors
Philip J. Mease¹, William Tillett², Xiaolan Ye³, Christopher Saffore⁴, Molly Edwards⁵, Isabel Truman⁵, Sophie Barlow⁶, Jayne Stigler⁷, Bhumik Parikh⁸ and Daniel Aletaha⁹, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, ³AbbVie Inc., Mettawa, IL, ⁴AbbVie Inc., waukegan, IL, ⁵Adelphi Real World, Bollington, United Kingdom, ⁶AbbVie, North Chicago, IL, ⁷AbbVie, Round Lake, IL, ⁸AbbVie, Hillsborough Township, NJ, ⁹Medical University Vienna, Wien, Austria
Background/Purpose: The aim of this study was to compare the effectiveness of switching from a first-line TNFi to upadacitinib (UPA), an oral JAKi, versus cycling…
Abstract Number: 1413 • ACR Convergence 2025
Restless Legs Syndrome in Patients with Psoriatic Arthritis: Association with Inflammatory, Clinical Parameters, and Comorbidities
Esther Toledano¹, Carlos Villegas², Carolina Cristina Chacón³, Cristina Hidalgo Calleja³, Belén Miguel³, Laura Blanco³, Ana Turrión⁴, Olga Compán⁵, Manuel Martín⁴, Susana Gómez³ and Carlos Montilla³, ¹Rheumatology Service, San Carlos Clinical Hospital, Madrid, Spain, ²Faculty of Medicine, University of Salamanca, Salamanca, Spain, ³Rheumatology Service, University Hospital of Salamanca, Salamanca, Castilla y Leon, Spain, ⁴Rheumatology Service, University Hospital of Salamanca, Salamanca, Spain, ⁵Rheumatology Service, University Hospital of Salamanca, Carbajosa de la Sagrada, ³⁷¹⁹¹, Spain
Background/Purpose: Restless legs syndrome (RLS) is a chronic neurological disorder associated with brain iron metabolism. Although RLS has been linked to various immune-mediated inflammatory diseases,…
Abstract Number: 0590 • ACR Convergence 2025
Effect of Deucravacitinib Treatment on Disease Activity–Associated Plasma Biomarkers in Patients With Active Psoriatic Arthritis: Results From 2 Phase 3 Studies
Vinod Chandran¹, Oliver FitzGerald², Philip J. Mease³, Lihi Eder⁴, Jose Scher⁵, Christopher Ritchlin⁶, Dafna D. Gladman⁷, Walter P Maksymowych⁸, Coryandar Gilvary⁹, Aditi Basu Bal⁹, Eleni Vritzali¹⁰ and Jinqi Liu⁹, ¹Division of Rheumatology, Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto, and Gladman Krembil Psoriatic Arthritis Research Program, Krembil Research Institute, University Health Network, Toronto, Canada, ²UCD, Dublin ⁶, Dublin, Ireland, ³Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ⁴University of Toronto, Toronto, ON, Canada, ⁵New York University School of Medicine, New York, NY, ⁶University of Rochester Medical Center, Canandaigua, NY, ⁷Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁸Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁹Bristol Myers Squibb, Princeton, NJ, ¹⁰Bristol Myers Squibb, Boudry, Switzerland
Background/Purpose: Understanding how treatments affect disease-relevant biomarker expression is essential for advancing targeted therapies. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, has…
Abstract Number: 0557 • ACR Convergence 2025
Efficacy of Upadacitinib in Male and Female Patients with PsA: Results from the SELECT-PsA 1 and 2 Trials
Lihi Eder¹, Axel Hueber², Lucia Novelli³, Tianming Gao³, Jayne Stigler⁴, Zhiyuan Du³, Rodrigo García Salinas⁵, Grace Wright⁶ and Sofia Ramiro⁷, ¹University of Toronto, Toronto, ON, Canada, ²Klinikum Nuernberg, Nuernberg, Germany, ³AbbVie, North Chicago, IL, ⁴AbbVie, Round Lake, IL, ⁵Hospital Italiano La Plata, La Plata, Argentina, ⁶Grace C Wright MD PC, New York, NY, ⁷Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Biologic sex can impact both clinical phenotype and therapeutic response in PsA.1–3 Previous studies have suggested that male patients (pts) may achieve better treatment…
Abstract Number: 0529 • ACR Convergence 2025
Anti-PeptidylArginine Deiminase-2 (anti-PAD2) Autoantibodies in Psoriatic Arthritis
Ana-Maria Orbai¹, Hong Wang², Maria Grecu³, Ning Meng⁴, Ji Soo Kim⁵, Clifton Bingham⁴, Uzma Haque², John Miller⁴, Felipe Andrade², Erika Darrah⁶ and Eleni Tiniakou⁷, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³River Hill High School, Clarksville, MD, ⁴Johns Hopkins University, Baltimore, MD, ⁵Johns Hopkins, Baltimore, MD, ⁶Astra Zeneca, Gaithersburg, MD, ⁷UT Health Science Houston, Houston, TX
Background/Purpose: Citrullinated cathelicidin (LL37), a human-derived antimicrobial peptide, is an autoantigen in psoriatic arthritis (PsA).1 LL37 citrullination by peptidylarginine deiminase (PAD) enzymes attenuates immune activation…
Abstract Number: 0112 • ACR Convergence 2025
Proteome-wide Mendelian Randomization Identifies Therapeutic Targets in Psoriatic Arthritis
Quan Li¹ and Proton Rahman², ¹University of Toronto, Toronto, Canada, ²Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Discipline of Medicine, Memorial University of Newfoundland, St. John's, Canada
Background/Purpose: While numerous proteins have been linked to psoriatic arthritis (PsA), the causal nature of these associations remains unconfirmed. This study aims to employ a…
Abstract Number: 2372 • ACR Convergence 2025
Treatment Outcome and Persistence of IL-23 Inhibitors in Real World Cohort of PsA Patients- A Retrospective Study
Dana Rosenberg¹, Dafne capelusnik², Shai Shtrozberg³, Ori Elkayam⁴ and Reut Tzemach⁵, ¹Sourasky medical center Tel aviv ISRAEL, TEL AVIV, Israel, ²Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ³Sourasky medical center Tel aviv ISRAEL, TEL AVIV, ⁴Tel Aviv medical center, Tel Aviv, Israel, ⁵Sourasky medical center Tel aviv ISRAEL, Tel Aviv-Yafo, Israel
Background/Purpose: In recent years, IL-23 inhibitors (IL23i)-have emerged as promising therapeutic options for psoriatic arthritis patients (PsA). Clinical trials have demonstrated their efficacy in both…
Abstract Number: 2344 • ACR Convergence 2025
Impact of Bimekizumab Use in Spondyloarthritis and Psoriatic Arthritis: Persistence Study in Routine Clinical Practice in Spain (BIMPACT study)
Cristina Valero¹, Chamaida Plasencia-Rodríguez², Maria Beatriz Paredes Romero³, Silvia Montes⁴, Josefina Marin⁵, Aranzazu Rubio⁶, Cristina Macía-Villa⁷, Laura Gonzalez Hombrado⁸, Maria Luisa Gonzalez Gomez⁹, Maria Carmen Ortega de la O¹⁰, Mercedes Morcillo Valle¹¹, Rosario Garcia Vicuña¹², EVA GLORIA TOMERO MURIEL¹², Diana Peiteado² and BEATRIZ JOVEN¹³, ¹Hospital de la Princesa, Madrid, Spain, ²Hospital Universitario La Paz, MADRID, Spain, ³Infanta Sofía University Hospital, Madrid, Spain, ⁴Hospital de Talavera, Talavera, Castilla-La Mancha, Spain, ⁵Hospital Universitario Rey Juan Carlos, Madrid, Spain, ⁶Hospital Universitario Infanta Cristina, Madrid, Spain, ⁷Hospital Universitario Ramon y Cajal, Madrid, Spain, ⁸Hospital Universitario del Tajo, Aranjuez (MADRID), Madrid, Spain, ⁹Hospital Universitario El Escorial, Majadahonda, Spain, ¹⁰Hospital Universitario Getafe, Madrid, Madrid, Spain, ¹¹Hospital El Escorial, San Lorenzo de El Es, Spain, ¹²Hospital Universitario de la Princesa, Madrid, Spain, ¹³H. Universitario ¹² Octubre, Madrid, Spain
Background/Purpose: Bimekizumab (BKZ) is a monoclonal antibody that simultaneously blocks IL-17A, IL-17F, and their heterodimer, key cytokines involved in the pathogenesis of spondyloarthritis (SpA) and…
Abstract Number: 2306 • ACR Convergence 2025
Prevalence and Clinical Significance of the Gastrointestinal Fat Halo Sign in Patients with Psoriatic Arthritis: A Cross-Sectional Study
Amir Haddad¹, Kathrien Mousa¹, Kateryna Milman¹, Najwan Nassrallah¹, Devy Zisman² and Sharbell Hashoul³, ¹Carmel Medical Centre, Haifa, Israel, ²Carmel Medical Center, Haifa, Israel, ³The Faculty of Humanities and Social Sciences. Uno Academic College, Haifa, Israel
Background/Purpose: The existence of a gut-joint axis is widely described in spondyloarthritis, linking intestinal dysbiosis, subclinical gut inflammation, and arthritis. The fat halo sign is…
Abstract Number: 1714 • ACR Convergence 2025
The perimenopause period is associated with increased levels of disease activity in psoriatic arthritis
Lihi Eder¹, Xianwei Li², Sahil Koppikar³, Iliana Lega⁴, Dafna D. Gladman⁵, Vinod Chandran¹ and Richard Cook⁶, ¹University of Toronto, Toronto, ON, Canada, ²Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Canada, ³Women's College Hospital & University of Toronto, Markham, ON, Canada, ⁴University of Toronto and Women’s College Hospital, Toronto, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁶University of Waterloo, Waterloo, Canada
Background/Purpose: Perimenopause is associated with a wide spectrum of symptoms, including mood changes, sleep disturbances, and joint pains. Limited information exists on the effect of…
Abstract Number: 1448 • ACR Convergence 2025
Influence of Sex on the Therapeutic Persistence of Guselkumab in Psoriatic Disease: a Retrospective National Cohort Study
Laure Gossec¹, Pascal Claudepierre², Arnaud Constantin³, Denis Jullien⁴, Samira Chaalal⁵, Julie Baraut⁵, Laure Cipiere⁵, Laurène Gautier⁶, Pierre Lemire⁷ and Thierry Passeron⁸, ¹Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, ²Department of Rheumatology, CHU Henri Mondor, AP-HP, Créteil, France, Creteil, France, ³Department of Rheumatology, Toulouse University Hospital, Toulouse University and INSERM U¹²⁹¹, France, Toulouse, France, ⁴Hospices Civils de Lyon, Hôpital E. Herriot Department of Dermatologie, Lyon F-⁶⁹⁰⁰³ ; CIRI, Centre International de Recherche en Infectiologie, Team EIA : Epidermal immunity & Allergy, INSERM, U¹¹¹¹; Univ Lyon; Université de Lyon ¹; Ecole Normale Supérieure de Lyon; CNRS, UMR ⁵³⁰⁸, Lyon, France., Lyon, France, ⁵Johnson & Johnson, Issy les moulineaux, France, ⁶Johnson & Johson, Issy les Moulineaux, France, ⁷IQVIA, Real World Solutions, Paris, France, Paris, France, ⁸Johnson & Johnson, Nice, France
Background/Purpose: Psoriatic disease, including psoriasis (Pso) and psoriatic arthritis (PsA), seems to affect male and female patients differently in clinical presentation, disease progression and advanced…
Abstract Number: 1411 • ACR Convergence 2025
Defining Minimal Disease Activity (MDA) in Psoriatic Arthritis (PsA) with the inclusion of Psoriatic Arthritis Impact of Disease (PsAID) scores rather than Health Assessment Questionnaire (HAQ)
Conor Coyle¹, Sarah Yazji², Sruthi Murthy³, Philip Helliwell⁴, Andra Balanescu⁵, Juan Cañete⁶, Emmanuelle Dernis⁷, Uta Kiltz⁸, Ying Ying Leung⁹, Ana-Maria Orbai¹⁰, PENELOPE PALOMINOS¹¹, Josef Smolen¹², Maarten de Wit¹³, Laure Gossec¹⁴ and Laura Coates¹⁵, ¹Oxford University Hospitals, Reading, United Kingdom, ²South Texas Health System GME Consortium, Texas A&M College of Medicine, Texas, USA, College Station, TX, ³Oxford University Hospitals NHS Foundation Trust, Oxford, UK, Oxford, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, ⁵UNIVERSITY OF MEDICINE AND PHARMACY CAROL DAVILA, Bucharest, Romania, ⁶Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, ⁷Rheumatology Department, Le Mans Central Hospital, Le Mans, France, LE MANS, France, ⁸Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁹Rheumatology Department, Singapore General Hospital, Singapore, Singapore, Singapore, Singapore, ¹⁰Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ¹¹Hospital Lifeplus Litoral Norte, Xangri-lá, Brazil, Porto Alegre, Rio Grande do Sul, Brazil, ¹²Division of Rheumatology, Department of Medicine ³, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ¹³Patient Research Partner, Stichting Tools, Amsterdam, Netherlands, ¹⁴Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, ¹⁵Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom
Background/Purpose: Treat to target management is recommended in psoriatic arthritis (PsA) to improve disease control and patient quality of life. Minimal disease activity (MDA) criteria…
Abstract Number: 0587 • ACR Convergence 2025
Regulatory Role of IL17 F in the Pannus Formation of Psoriatic Arthritis: A Comparative Study with IL-17A
Siba Raychaudhuri¹, Christine Abria² and Smriti K Raychaudhuri³, ¹UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ²Sacramento VA Medical Center, Mather, CA, ³Sacramento VA Medical Center, Davis, CA
Background/Purpose: IL-17A and IL-17F are the key inflammatory mediators in the IL-17 cytokine family (IL-17A to IL-17F). IL-17A is the widely recognized inflammatory cytokine in…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].